<![CDATA[Mundipharma 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=36865>Sun, 03 May 2026 21:45:43 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients]]>https://www.newswire.co.kr/newsRead.php?no=1033343Tue, 28 Apr 2026 15:40:00 +0900<![CDATA[문디파마, 동종 조혈모세포이식 환자 침습성 진균 질환 예방 위한 REZZAYO® 제3상 임상 긍정적 결과 발표]]>https://www.newswire.co.kr/newsRead.php?no=1033344Tue, 28 Apr 2026 15:40:00 +0900<![CDATA[Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)]]>https://www.newswire.co.kr/newsRead.php?no=1020399Sun, 12 Oct 2025 11:00:00 +0900<![CDATA[문디파마, 레자요®에 대한 제3상 ReSPECT 임상 시험에서 환자 등록 완료 발표]]>https://www.newswire.co.kr/newsRead.php?no=1020400Sun, 12 Oct 2025 11:00:00 +0900<![CDATA[Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis]]>https://www.newswire.co.kr/newsRead.php?no=917768Wed, 27 Jan 2021 10:58:08 +0900<![CDATA[Julie Dehaene-Puype and Erik Nordkamp appointed as new regional Commercial Officers for Mundipharma]]>https://www.newswire.co.kr/newsRead.php?no=917478Tue, 19 Jan 2021 17:40:45 +0900